ZA200808334B - Cancer treatment combining lymphodepleting agent with CTLs and cytokines - Google Patents

Cancer treatment combining lymphodepleting agent with CTLs and cytokines

Info

Publication number
ZA200808334B
ZA200808334B ZA200808334A ZA200808334A ZA200808334B ZA 200808334 B ZA200808334 B ZA 200808334B ZA 200808334 A ZA200808334 A ZA 200808334A ZA 200808334 A ZA200808334 A ZA 200808334A ZA 200808334 B ZA200808334 B ZA 200808334B
Authority
ZA
South Africa
Prior art keywords
ctls
cytokines
cancer treatment
treatment combining
lymphodepleting agent
Prior art date
Application number
ZA200808334A
Other languages
English (en)
Inventor
Zeling Cai
Ann Moriarty
Per A Peterson
Jon M Richards
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200808334B publication Critical patent/ZA200808334B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464456—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200808334A 2006-03-01 2008-09-30 Cancer treatment combining lymphodepleting agent with CTLs and cytokines ZA200808334B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77851606P 2006-03-01 2006-03-01

Publications (1)

Publication Number Publication Date
ZA200808334B true ZA200808334B (en) 2009-12-30

Family

ID=38475344

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200808334A ZA200808334B (en) 2006-03-01 2008-09-30 Cancer treatment combining lymphodepleting agent with CTLs and cytokines

Country Status (14)

Country Link
US (1) US7993638B2 (fr)
EP (1) EP1996232B1 (fr)
JP (1) JP2009531303A (fr)
KR (1) KR20080098066A (fr)
CN (1) CN101437542A (fr)
AU (1) AU2007222080B2 (fr)
BR (1) BRPI0708446A2 (fr)
CA (1) CA2643337C (fr)
ES (1) ES2579762T3 (fr)
IL (1) IL193710A (fr)
MX (1) MX2008011302A (fr)
RU (1) RU2447900C2 (fr)
WO (1) WO2007103009A2 (fr)
ZA (1) ZA200808334B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
EP2841563B1 (fr) 2012-04-24 2019-06-12 Dan S. Kaufman Procédé de développement de cellules tueuses naturelles à partir de cellules souches
KR102095700B1 (ko) 2013-05-14 2020-04-01 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용
RU2689558C1 (ru) * 2013-11-22 2019-05-28 Селлектис Способ конструирования аллогенных и устойчивых к лекарственным препаратам т-клеток для иммунотерапии
CA3190002A1 (fr) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Recepteurs antigeniques chimeriques et procede de production
CN106132422A (zh) 2014-02-27 2016-11-16 莱斯拉公司 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法＆相关治疗方法
EP3320916B1 (fr) * 2014-03-17 2021-09-15 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten Médicament destiné à être utilisé dans un procédé permettant d'induire ou d'étendre une réponse immunitaire cytotoxique cellulaire
CA2945388A1 (fr) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Recepteurs d'antigenes chimeres (car) utilises dans un traitement et methodes de fabrication associees
WO2015164740A1 (fr) 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application de cellules souches pluripotentes induites pour générer des produits de thérapie cellulaire adoptive
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
US20170333480A1 (en) 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
WO2016073629A1 (fr) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Récepteurs d'antigènes chimériques (car) pour cibler sélectivement des complexes protéiques
CN107614062A (zh) 2015-03-12 2018-01-19 加利福尼亚大学董事会 用RORγ抑制剂治疗癌症的方法
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
CN107980042B (zh) 2015-06-11 2021-10-08 莱斯拉公司 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
WO2017075147A1 (fr) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Molécules de récepteur d'antigène chimérique et leurs utilisations
CN109068658A (zh) * 2015-11-18 2018-12-21 杜克大学 用于治疗癌症的肿瘤浸润淋巴细胞
CN105505873A (zh) * 2016-02-29 2016-04-20 时宏珍 HLA-A0201限制性抗Her2-neu抗原特异性CTL的制备方法
CA3025667A1 (fr) 2016-06-08 2017-12-14 Intrexon Corporation Recepteurs antigeniques chimeriques specifiques de cd33
KR20230107408A (ko) 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
WO2018132494A1 (fr) 2017-01-10 2018-07-19 Intrexon Corporation Modulation de l'expression de polypeptides par l'intermédiaire de nouveaux systèmes d'expression de commutateurs géniques
EP3630813A1 (fr) 2017-05-24 2020-04-08 Novartis AG Protéines greffées d'anticorps-cytokine et procédés d'utilisation dans le traitement du cancer
CN110997920A (zh) 2017-06-07 2020-04-10 英特拉克森公司 新型细胞标签的表达
US11919937B2 (en) 2018-01-09 2024-03-05 Board Of Regents, The University Of Texas System T cell receptors for immunotherapy
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
MX2021002449A (es) 2018-09-04 2021-08-05 Treos Bio Ltd Vacunas peptidicas.
EA202191463A1 (ru) 2018-11-28 2021-10-13 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
CA3121210A1 (fr) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Procedes pour l'expansion ex vivo de cellules tueuses naturelles et utilisation associee
WO2020200481A1 (fr) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Traitement à l'interleukine-2 (il2) et à l'interféron (ifn)
CN115052973A (zh) 2019-11-06 2022-09-13 贝勒医学院 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法
US20230079539A1 (en) 2020-02-10 2023-03-16 Board Of Regents, The University Of Texas System Methods for rapid cloning and expression of hla class i cells
CN115461062A (zh) * 2020-04-28 2022-12-09 阿基里斯治疗英国有限公司 T细胞疗法
IL298558A (en) 2020-05-27 2023-01-01 Antion Biosciences Sa Adapter molecules redirect CAR T cells to the antigen of interest
US20210369828A1 (en) * 2020-05-28 2021-12-02 Case Western Reserve University Plant virus based cancer antigen vaccine
WO2023281097A1 (fr) 2021-07-09 2023-01-12 Immunic Ag Méthodes de traitement du cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
AU720201B2 (en) 1995-03-08 2000-05-25 Scripps Research Institute, The Antigen presenting system and methods for activation of T-cells
DK0969865T3 (da) 1996-05-23 2007-03-19 Scripps Research Inst Systemer til præsentation af MHC-antigener af klasse II og fremgangsmåder til aktivering af CD4+-T-celller
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
NZ521715A (en) * 2000-04-28 2008-01-31 Mannkind Corp Method of identifying and producing antigen peptides and use thereof as vaccines
US20040071671A1 (en) * 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
JP2005514029A (ja) 2001-11-07 2005-05-19 マンカインド コーポレイション 抗原提示細胞におけるエピトープ同調
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
JP2005139118A (ja) * 2003-11-07 2005-06-02 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法

Also Published As

Publication number Publication date
US7993638B2 (en) 2011-08-09
IL193710A0 (en) 2011-08-01
CA2643337A1 (fr) 2007-09-13
EP1996232A4 (fr) 2010-08-04
IL193710A (en) 2015-04-30
US20090324539A1 (en) 2009-12-31
WO2007103009A3 (fr) 2008-10-09
EP1996232B1 (fr) 2016-04-06
JP2009531303A (ja) 2009-09-03
CA2643337C (fr) 2016-01-12
RU2008138880A (ru) 2010-04-10
EP1996232A2 (fr) 2008-12-03
RU2447900C2 (ru) 2012-04-20
MX2008011302A (es) 2008-11-04
ES2579762T3 (es) 2016-08-16
BRPI0708446A2 (pt) 2011-06-07
AU2007222080A1 (en) 2007-09-13
KR20080098066A (ko) 2008-11-06
CN101437542A (zh) 2009-05-20
WO2007103009A2 (fr) 2007-09-13
AU2007222080B2 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
IL193710A0 (en) CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES
HK1136822A1 (en) Therapeutic compounds and their use in cancer
EP1994181A4 (fr) Identification et utilisation de novopeptides pour le traitement du cancer
IL186662A0 (en) Combination cancer therapy with
EP1996182A4 (fr) Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases
IL201211A (en) K3 ip-alpha quinoxaline inhibitors for use in combination with chemotherapeutic agents for use in the treatment of cancer
PT2101731T (pt) Endoxifeno para utilização no tratamento de cancro
EP1906948A4 (fr) Traitement du cancer
EP2059498A4 (fr) Traitement du cancer
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
EP2025347A4 (fr) Agent prophylactique et thérapeutique contre le cancer
EP1863520A4 (fr) Utilisation de l'interleukine 17e pour le traitement du cancer
EP2123266A4 (fr) Agent thérapeutique contre le cancer et agent anti-carcinogène
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
EP2144887A4 (fr) Doses et méthodes de traitement du cancer
HK1110224A1 (en) Therapeutic agent for cancer
IL199911A0 (en) 3-cinnolinecarboxamide derivatives and their use for treating cancer
HK1151971A1 (en) Compounds for use in the treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
GB0603901D0 (en) Cancer imaging and treatment
GB0507685D0 (en) Cancer treatment
GB0710871D0 (en) Cancer treatment
EP2224932A4 (fr) Traitement du cancer à l'aide d'une combinaison d'un inhibiteur de cox-2 et d'un anti-métabolite
GB0600903D0 (en) Treatment of cancer